Pathology Oncology Research

, Volume 8, Issue 4, pp 245–251 | Cite as

Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast

  • Jana Šmardová
  • Šárka Pavlová
  • Hana Koukalová


Tumor suppressor p53 is transcription factor that participates in control of many cellular functions. Somatic mutations of the p53 gene are frequently detected in human cancers. Several methods can be used for identification of p53 mutations, including FASAY — functional analysis of separated alleles in yeast. FASAY distinguishes yeast colonies expressing functional p53 protein from colonies producing a dysfunctional p53 protein simply on the basis of color. The validity of the method depends on a low background level. There are several sources of background as PCR-induced point mutations, low quality of RNA and alternative splicing of intron 9 affecting the p53 carboxy-terminus. In the present work we show that FASAY can be successfully used for analysis of mRNA isolated from blood samples that were collected and stored for 24 hours at 0°C without undesired increase of background. We also measured fidelity of several commonly used DNA polymerases and determined the most suitable kinds of Pfu DNA polymerases for FASAY. Reaction conditions described in this report allow routine analysis of p53 status in leukemic cells using FASAY.


tumor suppressor p53 FASAY DNA polymerase fidelity mRNA stability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baker SJ, Markowitz S, Fearon ER, et al: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912–915, 1990PubMedCrossRefGoogle Scholar
  2. 2.
    Bi S, Hughes T, Bungey J, et al: p53 in chronic myeloid leukemia cell lines. Leukemia 6: 839–842, 1992PubMedGoogle Scholar
  3. 3.
    Camplejohn RS, Rutheford J: p53 functional assay: detecting p53 mutations in both the germline and in sporadic tumours. Cell Prolif 34: 1–14, 2001PubMedCrossRefGoogle Scholar
  4. 4.
    Di Como CJ, Prives C: Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16: 2527–2539, 1998PubMedCrossRefGoogle Scholar
  5. 5.
    Duddy PM, Hanby AM, Barnes DM, Camplejohn RS: Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional Assay J Mol Diagnostics 2: 139–144, 2000Google Scholar
  6. 6.
    Flaman JM, Frebourg T, Moreau V, et al: A rapid PCR fidelity assay. Nucl Acid Res 22: 3259–3260, 1994CrossRefGoogle Scholar
  7. 7.
    Flaman JM., Frebourg T, Moreau V, et al: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963–3967, 1995PubMedCrossRefGoogle Scholar
  8. 8.
    Flaman JM, Waridel F, Estreicher A, et al: The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12: 813–818, 1996PubMedGoogle Scholar
  9. 9.
    Flaman JM, Robert V, Lenglet S, et al: Identification of of human p53 mutations with differential effects on the bax and p21 promoters using functional assay in yeast. Oncogene 16: 1369–1372, 1998PubMedCrossRefGoogle Scholar
  10. 10.
    Inga A, Iannone R, Monti P, et al: Determining mutational fingerprints at the human p53 locus with a yeast functional assay: A new tool for molecular epidemiology. Oncogene 14: 1307–1313, 1997PubMedCrossRefGoogle Scholar
  11. 11.
    Ishioka C, Frebourg T, Yan YX, et al: Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat.Genet. 5: 124–129, 1993PubMedCrossRefGoogle Scholar
  12. 12.
    Kashiwazaki H, Tonoki H, Tada M, et al: High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 15: 2667–2674, 1997PubMedCrossRefGoogle Scholar
  13. 13.
    Meinhold-Heerlein I, Ninci E, Ikenberg H, et al: Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60: 176–188, 2001PubMedCrossRefGoogle Scholar
  14. 14.
    O’Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National cancer institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300, 1997PubMedGoogle Scholar
  15. 15.
    Rizzo MG, Zepparoni A, Cristofanelli B, et al: Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. Brit J Cancer 77: 1429–1438, 1998PubMedGoogle Scholar
  16. 16.
    Smardova J, Vagunda V, Jandakova E, et al: p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry. Neoplasma 46: 384–389, 1999PubMedGoogle Scholar
  17. 17.
    Smardova J, Nemajerova A, Trbusek M, et al: Rare somatic p53 mutation identified in breast cancer:A case report. Tumor Biol 22: 59–66, 2001CrossRefGoogle Scholar
  18. 18.
    Soussi T, Legros Y, Lubin R, et al: Multifactorial analysis of p53 alteration in human cancer: A review. Int. J. Cancer Inst. 88: 173–182, 1996Google Scholar
  19. 19.
    Stotz A, Linder P: ADE2 gene from Saccharomyces cerevisiae: Sequence and new vwctors. Gene 95: 91–98, 1990PubMedCrossRefGoogle Scholar
  20. 20.
    Waridel F, Estreicher A, Bron L, et al: Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract. Oncogene 14: 163–169, 1997PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2002

Authors and Affiliations

  • Jana Šmardová
    • 1
  • Šárka Pavlová
    • 1
  • Hana Koukalová
    • 1
  1. 1.Department of Experimental OncologyMasaryk Memorial Cancer InstituteBrnoCzech Republic

Personalised recommendations